Oric Pharmaceuticals: T. Rowe Price reports 4.9%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oric Pharmaceuticals, Inc. (ORIC) was the subject of an ownership amendment in which T. Rowe Price Associates, Inc. reported beneficial ownership of 5,088,495 common shares, equal to 4.9% of the class. The amendment identifies September 30, 2026, as the event date. T. Rowe Price reported sole voting power over 5,079,985 shares and sole dispositive power over 5,088,495 shares, with no shared voting or dispositive power. It stated that the filing is not an admission of beneficial ownership and expressly denied being the beneficial owner.
Key Figures
Key Terms
beneficial ownership regulatory
sole voting power regulatory
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.